Recently, the single target BCL-2 inhibitor venetoclax, which was approved by the FDA for acute myeloid leukemia and chronic lymphocytic leukemia [40], showed therapeutic effect on multiple PDXs of SCLC [41]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.